202 related articles for article (PubMed ID: 11159798)
21. Several major antiepileptic drugs are substrates for human P-glycoprotein.
Luna-Tortós C; Fedrowitz M; Löscher W
Neuropharmacology; 2008 Dec; 55(8):1364-75. PubMed ID: 18824002
[TBL] [Abstract][Full Text] [Related]
22. Computational model of intracellular pharmacokinetics of paclitaxel.
Kuh HJ; Jang SH; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2000 Jun; 293(3):761-70. PubMed ID: 10869374
[TBL] [Abstract][Full Text] [Related]
23. In vitro cytotoxic activity of cationic paclitaxel nanoparticles on MDR-3T3 cells.
Niu G; Castro CH; Nguyen N; Sullivan SM; Hughes JA
J Drug Target; 2010 Jul; 18(6):468-76. PubMed ID: 20059301
[TBL] [Abstract][Full Text] [Related]
24. Phosphatidylcholine and phosphatidylethanolamine behave as substrates of the human MDR1 P-glycoprotein.
Bosch I; Dunussi-Joannopoulos K; Wu RL; Furlong ST; Croop J
Biochemistry; 1997 May; 36(19):5685-94. PubMed ID: 9153408
[TBL] [Abstract][Full Text] [Related]
25. Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Jachez B; Loor F
Anticancer Drugs; 1993 Dec; 4(6):605-15. PubMed ID: 7905300
[TBL] [Abstract][Full Text] [Related]
26. Reversal of drug resistance in P-glycoprotein-expressing T-cell acute lymphoblastic CEM leukemia cells by copper N-(2-hydroxy acetophenone) glycinate and oxalyl bis (N-phenyl) hydroxamic acid.
Majumder S; Dutta P; Mukherjee P; Datta ER; Efferth T; Bhattacharya S; Choudhuri SK
Cancer Lett; 2006 Nov; 244(1):16-23. PubMed ID: 16410038
[TBL] [Abstract][Full Text] [Related]
27. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
28. Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.
Xiao JJ; Foraker AB; Swaan PW; Liu S; Huang Y; Dai Z; Chen J; Sadée W; Byrd J; Marcucci G; Chan KK
J Pharmacol Exp Ther; 2005 Apr; 313(1):268-76. PubMed ID: 15634944
[TBL] [Abstract][Full Text] [Related]
29. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
30. Study of sodium orthovanadate as a reverser of multidrug resistance on lymphoblastic leukemic CEM/VLB100 cells.
Colin M; Madoulet C; Baccard N; Arsac F; Jardillier JC
Anticancer Res; 1994; 14(6A):2383-7. PubMed ID: 7825977
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo characterizations of tetrandrine on the reversal of P-glycoprotein-mediated drug resistance to paclitaxel.
Zhu X; Sui M; Fan W
Anticancer Res; 2005; 25(3B):1953-62. PubMed ID: 16158930
[TBL] [Abstract][Full Text] [Related]
32. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.
Choi CH; Kang G; Min YD
Planta Med; 2003 Mar; 69(3):235-40. PubMed ID: 12677527
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin.
Barthomeuf C; Grassi J; Demeule M; Fournier C; Boivin D; Béliveau R
Cancer Chemother Pharmacol; 2005 Aug; 56(2):173-81. PubMed ID: 15824923
[TBL] [Abstract][Full Text] [Related]
34. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
[TBL] [Abstract][Full Text] [Related]
35. Paclitaxel sensitizes multidrug resistant cells to radiation.
Mote PA; Davey MW; Davey RA; Oliver L
Anticancer Drugs; 1996 Feb; 7(2):182-8. PubMed ID: 8740723
[TBL] [Abstract][Full Text] [Related]
36. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
[TBL] [Abstract][Full Text] [Related]
37. Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia.
Verrills NM; Po'uha ST; Liu ML; Liaw TY; Larsen MR; Ivery MT; Marshall GM; Gunning PW; Kavallaris M
J Natl Cancer Inst; 2006 Oct; 98(19):1363-74. PubMed ID: 17018783
[TBL] [Abstract][Full Text] [Related]
38. Time dependence of [3H]-vincristine accumulation by L1210 mouse leukemic cells. Effect of P-glycoprotein overexpression.
Breier A; Stefanková Z; Barancík M; Tribulová N
Gen Physiol Biophys; 1994 Aug; 13(4):287-98. PubMed ID: 7890145
[TBL] [Abstract][Full Text] [Related]
39. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
40. Syl611, a novel semisynthetic taxane derivative, reverses multidrug resistance by p-glycoprotein inhibition and facilitating inward transmembrane action.
Zhang Y; Li H; Wang H; Su F; Qu R; Yin D; Dai J; Li Y; Chen X
Cancer Chemother Pharmacol; 2010 Oct; 66(5):851-9. PubMed ID: 20052473
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
